Patents by Inventor Stephen W Kaldor

Stephen W Kaldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230081390
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
  • Patent number: 11591331
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 28, 2023
    Assignee: XINTHERA, INC.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • Publication number: 20230053465
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: July 7, 2022
    Publication date: February 23, 2023
    Inventors: Robert L. HOFFMAN, Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR
  • Publication number: 20230023761
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 26, 2023
    Inventors: Bohan JIN, Qing DONG, Gene HUNG, Stephen W. KALDOR
  • Publication number: 20230021554
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: August 19, 2022
    Publication date: January 26, 2023
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Publication number: 20220402892
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: July 19, 2022
    Publication date: December 22, 2022
    Inventors: Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR, Robert L. HOFFMAN
  • Publication number: 20220388990
    Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 8, 2022
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • Publication number: 20220356160
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: May 6, 2022
    Publication date: November 10, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
  • Publication number: 20220348574
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: April 19, 2022
    Publication date: November 3, 2022
    Inventors: Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR, Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN
  • Publication number: 20220340543
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 27, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • Patent number: 11447493
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 20, 2022
    Inventors: Toufike Kanouni, Lee Arnold, Stephen W. Kaldor, Eric A. Murphy
  • Patent number: 11407737
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 9, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
  • Publication number: 20220235035
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 28, 2022
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Patent number: 11377431
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: July 5, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • Publication number: 20220153706
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: June 23, 2021
    Publication date: May 19, 2022
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Publication number: 20220112170
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: October 11, 2021
    Publication date: April 14, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
  • Publication number: 20220089569
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 24, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA